Osteosarcoma Treatment with Dendritic Cells in Germany
Osteosarcoma tumors are a rare but aggressive form of bone cancer, most commonly affecting adolescents and young adults. In Germany, approximately 60 children and adolescents under 18 are diagnosed with osteosarcoma each year, accounting for about 2.6% of all pediatric malignancies in this age group. This cancer typically...
Esophageal Cancer Guideline: All Treatment Options
Esophageal cancer remains one of the most lethal malignancies of the digestive tract, responsible for approximately one in twenty cancer-related deaths globally. More than 500,000 new cases were diagnosed worldwide in 2022, with the burden especially high in East Asia and certain regions of Africa. In the United States...
Treatment of soft tissue sarcoma with dendritic cells
Soft tissue sarcomas are rare malignant tumors that develop in muscles, fat, cartilage, blood vessels, and other non-epithelial tissues throughout the body. With approximately 13,520 new cases expected in the United States in 2025, these cancers represent less than 1% of all cancer diagnoses. While advanced sarcomas differ...
Dendritic Cell Therapy for Lung Cancer Treatment in Germany
Imagine a treatment that boosts your own immune response to fight lung cancer with precision, causing virtually no side effects while you maintain your daily routine. Dendritic cell therapy offers this possibility to patients at any cancer stage, showing effectiveness rates of 50-65% across various cancer types. With lung cancer affecting 226,650 new...
Stem Cell Therapy for Optic Nerve Atrophy (ONA)
Optic Nerve Atrophy (ONA) is a progressive ocular condition in which the optic nerve – responsible for transmitting visual information from the eye to the brain – undergoes degeneration. This damage leads to gradual vision loss and, in severe cases, complete blindness. ONA is not a disease itself but a final stage of various underlying pathologies...
Prostate cancer treatment with dendritic cells in Germany
Dendritic cell prostate cancer treatment represents a groundbreaking immunotherapy approach, recognized by the 2011 Nobel Prize in Physiology or Medicine, awarded to Ralph Steinman. This innovative method can be prescribed to men of all ages and at any stage of prostate cancer, serving as an effective addition to standard treatment....
Innovative Treatment for Glioblastoma in Germany: Dendritic Cell Therapy for Cancer
Standard therapy for glioblastoma includes surgical removal of the tumor in combination with chemotherapy or radiation therapy. With standard treatment of glioblastoma, the average life expectancy after diagnosis is 15-17 months, and the 5-year survival rate does not exceed 5-10%. Supplementing the standard protocol with the dendritic cell...
Cervical cancer treatment with dendritic cell therapy
Cervical cancer affects approximately 660,000 women worldwide each year, making it the fourth most common cancer among women globally. While early detection typically offers excellent cure rates, advanced cases require innovative treatment approaches. Dendritic cell therapy represents a promising personalized immunotherapy...
